Metformin and the Development of Asthma in Patients with Type 2 Diabetes

Fu-Shun Yen, Chih-Cheng Hsu, Ying-Hsiu Shih, Wei-Lin Pan, James Cheng-Chung Wei and Chii-Min Hwu
Additional contact information
Fu-Shun Yen: Dr. Yen’s Clinic, Taoyuan 33354, Taiwan
Chih-Cheng Hsu: Institute of Population Health Sciences, National Health Research Institutes, Miaoli County 35053, Taiwan
Ying-Hsiu Shih: Management Office for Health Data, China Medical University Hospital, Taichung 40459, Taiwan
Wei-Lin Pan: Department of Internal Medicine, Mackay Memorial Hospital, Taipei 10449, Taiwan
James Cheng-Chung Wei: Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
Chii-Min Hwu: Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11221, Taiwan

IJERPH, 2022, vol. 19, issue 13, 1-13

Abstract: We conducted this study to compare the risks of asthma development and exacerbation between metformin users and nonusers. Overall, 57,743 propensity score-matched metformin users and nonusers were identified from Taiwan’s National Health Insurance Research Database between 1 January 2000, and 31 December 2017. We used the Cox proportional hazards model with robust standard error estimates to compare the risks of asthma onset, exacerbation, and hospitalization for asthma in participants with type 2 diabetes (T2D). Compared with metformin nonuse, the aHRs (95% CI) for metformin use in asthma development, exacerbation, and hospitalization for asthma were 1.13 (1.06–1.2), 1.62 (1.35–1.95), and 1.5 (1.22–1.85), respectively. The cumulative incidences of asthma development, exacerbation, and hospitalization for asthma were significantly higher in metformin users than nonusers ( p < 0.001). A longer cumulative duration of metformin use for more than 728 days was associated with significantly higher risks of outcomes than metformin nonuse. Our study demonstrated that metformin users showed significantly higher risks of asthma development, exacerbation, and hospitalization for asthma than metformin nonusers. Moreover, metformin use for more than 728 days was associated with higher risks of outcomes. A randomized control study is warranted to verify our results.

Keywords: type 2 diabetes; metformin; asthma; exacerbation; hospitalization (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/13/8211/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/13/8211/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:13:p:8211-:d:855953

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().